Radiopharmaceuticals

Search documents
Lantheus (LNTH) 2025 Earnings Call Presentation
2025-06-17 12:48
Commercial Portfolio Performance - PYLARIFY achieved blockbuster status in 2024 with over $1 billion in sales[154], and Q1 2025 net sales reached $257.7 million[13] - DEFINITY remains the 1 utilized ultrasound enhancing agent, with Q1 2025 net sales of $79.2 million, a 3.5% year-over-year growth[24] Market Opportunities - The U S PSMA PET imaging market has a potential of over $3.5 billion by 2030, driven by expansion of radiotherapeutics and increasing clinical utility in BCR population[19, 20] - The U S ultrasound enhancing agent total addressable market is over $600 million[35] Pipeline Development - Lantheus is advancing an innovative pipeline of radiopharmaceuticals, including diagnostic and therapeutic candidates for prostate cancer, neuroendocrine tumors, and Alzheimer's disease[38, 40] - LNTH-2402, a GRPR-targeted radiotherapeutic, is expected to have an IND filing in Q4 2025, with Phase 1 initiation planned for 2026[109] Financial Highlights - As of March 31, 2025, Lantheus had $938.5 million in cash on hand and $98.8 million in free cash flow in Q1 2025[10] - The updated interim corporate financial guidance for the full year 2025 projects revenue between $1.550 billion and $1.585 billion, and adjusted fully diluted EPS between $6.60 and $6.70[142] Strategic Transactions - The acquisition of Evergreen Theragnostics closed in April 2025, strengthening radiodiagnostic and therapeutic capabilities[10, 165] - The acquisition of Life Molecular Imaging is expected to close by 2Q 2025, expanding the commercial portfolio and pipeline in Alzheimer's disease[10, 144]
Lantheus to Present at the 2025 Truist Securities MedTech Conference
Globenewswire· 2025-06-10 12:30
Core Viewpoint - Lantheus Holdings, Inc. is set to present at the 2025 Truist Securities MedTech Conference, highlighting its commitment to improving patient outcomes through radiopharmaceutical solutions [1]. Company Overview - Lantheus is a leading company in the radiopharmaceutical sector, focused on enabling clinicians to Find, Fight, and Follow disease for better patient outcomes [3]. - The company has been providing radiopharmaceutical solutions for nearly 70 years and is headquartered in Massachusetts, with additional offices in New Jersey, Canada, Sweden, and Switzerland [3]. Event Details - Brian Markison, the Chief Executive Officer of Lantheus, will present at the conference on June 17, 2025, at 8:40 a.m. ET [1]. - A live webcast of the presentation will be accessible through the Investors section of the company's website, with a replay available for at least 30 days post-event [2].
Lantheus to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Globenewswire· 2025-06-03 12:30
Core Viewpoint - Lantheus Holdings, Inc. is set to present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025, highlighting its commitment to improving patient outcomes through radiopharmaceuticals [1]. Company Overview - Lantheus is a leading company in the radiopharmaceutical sector, focused on enabling clinicians to Find, Fight, and Follow disease for better patient outcomes [3]. - The company has been providing radiopharmaceutical solutions for nearly 70 years and is headquartered in Massachusetts, with additional offices in New Jersey, Canada, and Sweden [3]. Event Details - Brian Markison, the Chief Executive Officer of Lantheus, will present at the conference on June 10, 2025, at 2:40 p.m. ET [1]. - A live webcast of the presentation will be accessible on the company's website, with a replay available for at least 30 days post-event [2].
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
Prnewswire· 2025-06-02 13:00
Core Insights - ASP Isotopes Inc. and Isotopia Molecular Imaging Ltd. have formed a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), essential for producing Terbium-161 (Tb-161), a promising medical isotope for targeted radiotherapeutics [1][2] Group 1: Partnership Details - The partnership aims to resolve supply challenges for Gd-160, facilitating the advancement of Tb-161-based therapies for various cancers, including prostate cancer and neuroendocrine tumors [2] - ASP Isotopes will utilize its proprietary Quantum Enrichment technology to provide enriched Gd-160, which is crucial for Tb-161 manufacturing [3] - The collaboration combines ASP Isotopes' large-scale isotope enrichment expertise with Isotopia's capabilities in commercial-scale medical isotope production [3] Group 2: Strategic Importance - The agreement is significant as it eliminates a major bottleneck in the development of Tb-161 therapies, supporting the growing demand for stable isotopes in the radiopharmaceutical industry [4] - Tb-161's dual mechanism of action allows for precise targeting of cancer cells while minimizing damage to healthy tissues, aligning with the oncology field's shift towards targeted radiotherapeutics [4] Group 3: Company Profiles - ASP Isotopes specializes in advanced isotope separation technologies, focusing on producing and commercializing highly enriched isotopes for healthcare and technology [5] - Isotopia is a global leader in medical isotope production, with facilities in Israel, Europe, and the U.S., and collaborates with researchers to develop novel radiopharmaceuticals [6] Group 4: Industry Outlook - This partnership positions both companies at the forefront of the radiopharmaceutical revolution, potentially expanding treatment options for cancer patients globally [7]
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan
Globenewswire· 2025-05-21 05:00
Core Insights - IBA has signed a contract with PET Pharm Bio to establish a PET and SPECT isotopes production center in Taipei, Taiwan, utilizing the Cyclone IKON cyclotron technology [1][4] - The new facility will produce novel radiopharmaceuticals for theranostics and targeted therapies, including isotopes such as Germanium-68, Iodine-123, Thallium-201, Zirconium-89, and Copper-64 [3][4] - The Cyclone IKON solution is expected to enhance PET Pharm Bio's capabilities in the radiopharmaceutical market, positioning it as a leader in Taiwan and Southeast Asia [4] Company Overview - PET Pharm Bio, established in 2011, focuses on the research, development, and production of radiopharmaceuticals, aiming to improve patient health and advance precision diagnosis and treatment in nuclear medicine [6] - IBA is recognized as the world leader in particle accelerator technology, providing equipment and services in proton therapy, industrial sterilization, and radiopharmaceuticals, with a workforce of approximately 2,100 employees [7] Financial Aspects - The typical end-user price for a Cyclone IKON solution ranges from EUR 10 million to EUR 15 million, depending on options and associated equipment [3]
IBA launches CASSY®, a new compact radiochemistry module to enhance efficiency in radiopharmaceuticals production
Globenewswire· 2025-05-13 05:00
Core Insights - IBA has launched CASSY, a compact synthesizer aimed at revolutionizing radiopharmaceutical production processes, particularly for radiometals and radiotracers [1][5]. Group 1: Product Features - CASSY enhances efficiency in radiopharmaceutical production through seamless integration into laboratory workflows, user-friendly interfaces, and versatility for purification and radiolabelling [2]. - The compact design allows stacking of up to six units in a single standard hot cell, optimizing space and increasing production potential, making it suitable for laboratories with limited space [3]. - CASSY is adaptable for a wide range of radioisotopes, catering to diverse research and clinical needs, and is positioned for future innovations like radiotheranostics [3]. Group 2: Components and Technology - CASSY utilizes specific cassettes developed by Fluidomica, which include all necessary components for radioisotope and radiopharmaceutical manufacturing processes [4]. - The cassettes are designed for single use, ensuring efficiency and reliability in production [4]. Group 3: Company Commitment and Leadership - Charles Kumps, President of IBA RadioPharma Solutions, emphasized that CASSY represents a significant advancement in theranostic innovation, enhancing the quality and reliability of radiopharmaceutical manufacturing [5]. - IBA continues to lead the radiopharmaceutical industry through its commitment to innovation and improving healthcare outcomes globally [5]. Group 4: Company Overview - IBA is recognized as the world leader in particle accelerator technology and is a major supplier in proton therapy, industrial sterilization, and dosimetry, employing approximately 2,100 people worldwide [7]. - The company is listed on the EURONEXT stock exchange and is a certified B Corporation, meeting high standards of social and environmental performance [8].
Lantheus Holdings(LNTH) - 2025 Q1 - Earnings Call Transcript
2025-05-07 13:02
Lantheus (LNTH) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Mark Kinarney - VP - Investor RelationsBrian Markison - CEO & DirectorPaul Blanchfield - PresidentAmanda Morgan - Chief Commercial OfficerRobert Marshall - CFO & TreasurerAnthony Petrone - Managing DirectorRichard Newitter - Managing DirectorMatthew Taylor - Managing DirectorYuan Zhi - Managing Director Conference Call Participants Roanna Ruiz - Senior Managing Director, Biotechnology AnalystNone - AnalystLarry Solow - Partn ...
Lantheus Holdings(LNTH) - 2025 Q1 - Earnings Call Transcript
2025-05-07 13:00
Lantheus (LNTH) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Good morning. Welcome to Lantheus First Quarter twenty twenty five Conference Call. All lines have been placed on mute. This call is being recorded and a replay will be available in the Investors section of the company's website approximately two hours after the completion of the call and will be archived for at least thirty days. I'll now turn the call over to Mark Kanarney, Vice President of Investor Relations. Mark? Speaker1 Thank yo ...
Lantheus Holdings(LNTH) - 2025 Q1 - Earnings Call Presentation
2025-05-07 11:16
Lantheus First Quarter 2025 Results May 7, 2025 © 2025 Lantheus. All rights reserved. 1 Agenda Highlights and Business Update Operational and Strategic Update Commercial Update Development Pipeline Update Financial Update Closing Remarks Q&A SPEAKERS Brian Markison CEO © 2025 Lantheus. All rights reserved. 2 Paul Blanchfield President Amanda Morgan Chief Commercial Officer Bob Marshall CFO and Treasurer Mark Kinarney Vice President, Investor Relations Safe Harbor Statements Cautionary Statement Regarding Fo ...
Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update
Globenewswire· 2025-05-07 11:00
Core Insights - Lantheus Holdings, Inc. reported a slight increase in worldwide revenue for Q1 2025, totaling $372.8 million, compared to $370.0 million in Q1 2024, reflecting a 0.8% growth [3][5] - The company experienced a significant decline in GAAP net income, which fell to $72.9 million from $131.1 million year-over-year, representing a 44.3% decrease [3][5] - Adjusted net income also decreased by 7.5% to $109.5 million, with adjusted fully diluted earnings per share dropping to $1.53 from $1.69, a 9.5% decline [3][5] Financial Performance - GAAP fully diluted earnings per share for Q1 2025 were $1.02, down from $1.87 in Q1 2024, marking a 45.5% decrease [3][5] - Free cash flow for the first quarter was reported at $98.8 million [5] - Operating income decreased by 4.3% to $102.1 million, while adjusted operating income fell by 7.1% to $144.3 million [6][27] Business Development - The company completed the acquisition of Evergreen Theragnostics and is in the process of acquiring Life Molecular Imaging, which is expected to close soon [2][10] - Lantheus announced a planned divestiture of its SPECT business to focus on PET radiodiagnostics and microbubbles [10] - Positive data from two pivotal studies of MK-6240 were reported, with plans to file a New Drug Application (NDA) in Q3 2025 [10] Revenue Breakdown - Sales of PYLARIFY were $257.7 million, a slight decrease of 0.5% from the previous year [6][24] - DEFINITY sales increased by 3.5% to $79.2 million [6][24] - Total revenues from strategic partnerships and other sources rose significantly by 65.1% to $10.7 million [24] Guidance and Outlook - The company provided updated guidance for FY 2025, projecting revenue between $1.550 billion and $1.585 billion, and adjusted fully diluted EPS between $6.60 and $6.70 [11]